 One-half of the study participants received a 200 mg of ridinilazole twice a day; the other half received 125 mg of vancomycin four times a day.In a Phase II proof-of-concept trial in CDI patients (‘CoDIFy’), ridinilazole showed statistical superiority in SCR rates compared to the standard of care, vancomycin.In this trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy.